Upper limb progression in Duchenne muscular dystrophy: Insights from a 36-month longitudinal study using the PUL 20.

IF 3.4 4区 医学 Q2 CLINICAL NEUROLOGY
Giorgia Coratti, Marika Pane, Sophia Paolucci, Luca Bello, Adele D'Amico, Angela Berardinelli, Michela Catteruccia, Giacomo De Luca, Riccardo Masson, Riccardo Zanin, Roberta Battini, Claudia Dosi, Silvia Frosini, Alice Gardani, Bianca Buchignani, Anna Capasso, Federica Ricci, Gianpaolo Cicala, Ilaria Cavallina, Enrica Rolle, Tiziana Enrica Mongini, Valeria Ada Sansone, Emilio Albamonte, Antonella Pini, Melania Giannotta, Chiara Panicucci, Riccardo Not, Claudio Bruno, Vincenzo Nigro, Esther Picillo, Elena Pegoraro, Eugenio Mercuri
{"title":"Upper limb progression in Duchenne muscular dystrophy: Insights from a 36-month longitudinal study using the PUL 20.","authors":"Giorgia Coratti, Marika Pane, Sophia Paolucci, Luca Bello, Adele D'Amico, Angela Berardinelli, Michela Catteruccia, Giacomo De Luca, Riccardo Masson, Riccardo Zanin, Roberta Battini, Claudia Dosi, Silvia Frosini, Alice Gardani, Bianca Buchignani, Anna Capasso, Federica Ricci, Gianpaolo Cicala, Ilaria Cavallina, Enrica Rolle, Tiziana Enrica Mongini, Valeria Ada Sansone, Emilio Albamonte, Antonella Pini, Melania Giannotta, Chiara Panicucci, Riccardo Not, Claudio Bruno, Vincenzo Nigro, Esther Picillo, Elena Pegoraro, Eugenio Mercuri","doi":"10.1177/22143602251355318","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Duchenne muscular dystrophy (DMD) is a progressive disorder. This study evaluates upper limb function in DMD patients using the Performance of Upper Limb 2.0 (PUL 2.0) over 36-months.</p><p><strong>Methods: </strong>Data were collected between 2011 and 2024. Patients with at least 36 months of follow-up were included. Mixed-effects models accounting for repeated measures evaluated 36-month PUL 2.0 changes by entry item and ambulatory status. The entry item assesses the overall upper limb function of the patient. Ambulant patients were defined as those able to walk 10 meters independently, transitioning patients as those who lost ambulation during the duration of the study and non-ambulant as those who had already lost ambulation at baseline.</p><p><strong>Results: </strong>A total of 219 patients provided 684 paired 36-month assessments. Ambulatory status significantly affected total, shoulder, elbow, and distal scores at baseline. The largest 36-month decline in total scores was found in the 58 transitioning patients (11.62 points, 95%CI = -12.40, 10.84), followed by non-ambulant and ambulant subgroups (n = 116 and n = 86 respectively). The largest declines were seen in patients with baseline entry score of 4 (-11.97, 95% CI = -13.48, -10.46) and 5 (-11.55, 95% CI = -12.46, -10.63), with smaller declines for other entry scores.ConclusionsThe 36-month analysis confirms a clear trend of functional decline across time points, with the transitioning group exhibiting the greatest changes in upper limb function. These findings provide valuable insights for designing trials and offer a reference for long-term comparison of treatment efficacy in both experimental and real-world setting.</p>","PeriodicalId":16536,"journal":{"name":"Journal of neuromuscular diseases","volume":" ","pages":"22143602251355318"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuromuscular diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/22143602251355318","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Duchenne muscular dystrophy (DMD) is a progressive disorder. This study evaluates upper limb function in DMD patients using the Performance of Upper Limb 2.0 (PUL 2.0) over 36-months.

Methods: Data were collected between 2011 and 2024. Patients with at least 36 months of follow-up were included. Mixed-effects models accounting for repeated measures evaluated 36-month PUL 2.0 changes by entry item and ambulatory status. The entry item assesses the overall upper limb function of the patient. Ambulant patients were defined as those able to walk 10 meters independently, transitioning patients as those who lost ambulation during the duration of the study and non-ambulant as those who had already lost ambulation at baseline.

Results: A total of 219 patients provided 684 paired 36-month assessments. Ambulatory status significantly affected total, shoulder, elbow, and distal scores at baseline. The largest 36-month decline in total scores was found in the 58 transitioning patients (11.62 points, 95%CI = -12.40, 10.84), followed by non-ambulant and ambulant subgroups (n = 116 and n = 86 respectively). The largest declines were seen in patients with baseline entry score of 4 (-11.97, 95% CI = -13.48, -10.46) and 5 (-11.55, 95% CI = -12.46, -10.63), with smaller declines for other entry scores.ConclusionsThe 36-month analysis confirms a clear trend of functional decline across time points, with the transitioning group exhibiting the greatest changes in upper limb function. These findings provide valuable insights for designing trials and offer a reference for long-term comparison of treatment efficacy in both experimental and real-world setting.

杜氏肌营养不良上肢进展:来自PUL 36个月纵向研究的见解
杜氏肌营养不良症(DMD)是一种进行性疾病。本研究使用上肢性能2.0 (PUL 2.0)评估DMD患者36个月以上的上肢功能。方法:收集2011 - 2024年的数据。随访至少36个月的患者被纳入研究。考虑重复测量的混合效应模型通过进入项目和流动状态评估36个月PUL 2.0变化。进入项目评估患者的整体上肢功能。流动患者被定义为能够独立行走10米的患者,过渡患者是指在研究期间失去行走能力的患者,非流动患者是指在基线时已经失去行走能力的患者。结果:共有219名患者提供了684对36个月的评估。基线时的活动状态显著影响总分、肩部、肘部和远端评分。36个月总分下降幅度最大的是58例移行患者(11.62分,95%CI = -12.40, 10.84),其次是非移行和移行亚组(n = 116和n = 86)。基线评分为4分(-11.97,95% CI = -13.48, -10.46)和5分(-11.55,95% CI = -12.46, -10.63)的患者下降幅度最大,其他评分下降幅度较小。结论36个月的分析证实了各时间点功能下降的明显趋势,其中过渡组上肢功能变化最大。这些发现为设计试验提供了有价值的见解,并为在实验和现实环境中长期比较治疗效果提供了参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of neuromuscular diseases
Journal of neuromuscular diseases Medicine-Neurology (clinical)
CiteScore
5.10
自引率
6.10%
发文量
102
期刊介绍: The Journal of Neuromuscular Diseases aims to facilitate progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis and treatment of acquired and genetic neuromuscular diseases (including muscular dystrophy, myasthenia gravis, spinal muscular atrophy, neuropathies, myopathies, myotonias and myositis). The journal publishes research reports, reviews, short communications, letters-to-the-editor, and will consider research that has negative findings. The journal is dedicated to providing an open forum for original research in basic science, translational and clinical research that will improve our fundamental understanding and lead to effective treatments of neuromuscular diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信